Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2012
04/26/2012WO2012052594A2 USE OF Dlk1 AS AN ANGIOGENESIS INHIBITOR
04/26/2012WO2012052390A1 N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3
04/26/2012WO2012052372A1 Tetrahydroquinoline derivatives used as ampk activators
04/26/2012WO2012052258A1 Compositions and methods for inhibiting expression of rrm2 genes
04/26/2012WO2012052230A1 Erbb3 binding antibody
04/26/2012WO2012052179A1 Amino derivatives for the treatment of proliferative skin disorders
04/26/2012WO2012052102A1 Quinoxaline derivates
04/26/2012WO2012051941A1 Uses of 15-benzylidene-14-deoxy-11,12-dehydroandrographolide derivatives in the preparation of antineoplastic drugs
04/26/2012WO2012028762A3 Cell lines and the use thereof for identifying drugs for thyroid carcinoma
04/26/2012WO2012024405A3 Curcumin compositions and uses thereof
04/26/2012WO2012024282A3 1,5-diphenyl-penta-1,4-dien-3-one compounds
04/26/2012WO2012021249A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
04/26/2012WO2012021247A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
04/26/2012WO2012016133A3 Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
04/26/2012WO2012012304A3 Method of treating refractory cancer
04/26/2012WO2012009289A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
04/26/2012WO2012006550A3 Methods and compositions for treatment of lipogenic virus related conditions
04/26/2012WO2012005550A3 Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
04/26/2012WO2011162558A9 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
04/26/2012WO2011155793A3 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
04/26/2012WO2011149909A3 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
04/26/2012WO2011118994A3 Nlk as a marker for diagnosis of liver cancer and as a therapeutic agent thereof
04/26/2012WO2011107572A8 Ferrocenyl flavonoids
04/26/2012US20120101427 Novel photosensitizer formulations for oral administration
04/26/2012US20120101325 Locally targeted anti-fibrotic agents and methods of use
04/26/2012US20120101163 Composition for inhibiting cancer metastasis
04/26/2012US20120101161 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
04/26/2012US20120101149 Betulinic Acid Derivatives and Methods of Use Thereof
04/26/2012US20120101136 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
04/26/2012US20120101134 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
04/26/2012US20120101129 Methylphenidate Derivatives and Uses of Them
04/26/2012US20120101127 Novel tetrahydroquinoline derivatives
04/26/2012US20120101124 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
04/26/2012US20120101123 Compounds
04/26/2012US20120101122 Imidazo[1,2 a] pyridine 6 carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture
04/26/2012US20120101119 N-substituted indenoisoquinolines and syntheses thereof
04/26/2012US20120101117 Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer
04/26/2012US20120101116 Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof
04/26/2012US20120101115 Compounds For Inducing Cellular Apoptosis
04/26/2012US20120101114 Inhibitors of bruton's tyrosine kinase
04/26/2012US20120101113 Inhibitors of bruton's tyrosine kinase
04/26/2012US20120101112 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
04/26/2012US20120101109 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4-[1, 3, 4-oxadiazole-2-yl] phenyl) pyridine-3- sulphonamide
04/26/2012US20120101105 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
04/26/2012US20120101102 Method for predicting therapeutic effect of chemotherapy on renal cell cancer
04/26/2012US20120101099 Histone deacetylase inhibitors
04/26/2012US20120101095 Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators
04/26/2012US20120101092 Small molecule inhibitors of mdm2 and the uses thereof
04/26/2012US20120101086 Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
04/26/2012US20120101084 Biological Markers Predictive of Anti-Cancer Response to Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
04/26/2012US20120101083 S1p1 agonists comprising a bicyclic n-containing ring
04/26/2012US20120101082 Vasopressin v1a antagonists
04/26/2012US20120101072 Triazole compounds that modulate hsp90 activity
04/26/2012US20120101068 Diphenyl sulfide derivatives and medicines containing same as active ingredient
04/26/2012US20120101064 Imidazole derivatives and their use as modulators of cyclin dependent kinases
04/26/2012US20120101059 Sulphated hyaluronic acids as regulator agents of the cytokine activity
04/26/2012US20120101057 Combined therapy of colorectal carcinoma
04/26/2012US20120101045 TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
04/26/2012US20120101044 Gold (iii) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents
04/26/2012US20120101029 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
04/26/2012US20120101028 Anti-inflammatory compounds and uses thereof
04/26/2012US20120101026 Compounds For Enzyme Inhibition
04/26/2012US20120101025 Compounds For Enzyme Inhibition
04/26/2012US20120101024 Methods and Compositions for Differentiating Embryonic Stem Cells
04/26/2012US20120100233 Compositions for treatment and prevention of diabetic complications using osteomeles schwerinae
04/26/2012US20120100227 Kinase protein binding inhibitors
04/26/2012US20120100220 Drug composition for treating tumor with polymeric micelle encapsulating anti-neoplastic
04/26/2012US20120100218 Intralymphatic Chemotherapy Drug Carriers
04/26/2012US20120100213 Pharmaceutical formulations of a substituted diaminopurine
04/26/2012US20120100207 Process for producing liposomes by two-step emulsification method utilizing outer aqueous phase containing specific dispersing agent, process for producing liposome dispersion or dry powder thereof using the process for producing liposomes, and liposome dispersion or dry powder thereof produced thereby
04/26/2012US20120100200 System And Method For Satellite Drug Delivery
04/26/2012US20120100182 Continuous Cell Programming Devices
04/26/2012US20120100175 Antrocin containing pharmaceutical compositions for inhibiting cancer cells
04/26/2012US20120100173 Methods for preparing and using multichaperone-antigen complexes
04/26/2012US20120100169 Vaccine for Cervical Cancer
04/26/2012US20120100162 Cyclophosphamide in Combination with Immune Therapeutics
04/26/2012US20120100161 Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy
04/26/2012US20120100159 Anti-tat226 antibodies and immunoconjugates
04/26/2012US20120100158 Anti ceacam1 antibodies and methods of using same
04/26/2012US20120100157 Biomarker and Method for Predicting Sensitivity to MET Inhibitors
04/26/2012US20120100156 Therapeutic Agent
04/26/2012US20120100154 Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
04/26/2012US20120100148 Anti-ferroportin 1 monoclonal antibodies and uses thereof
04/26/2012US20120100147 Novel antibodies and their uses in therapeutic and diagnostic methods
04/26/2012US20120100145 Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
04/26/2012US20120100144 Biomarker and Treatment for Cancer
04/26/2012US20120100138 The use of inhibitors of bruton's tyrosine kinase (btk)
04/26/2012US20120100135 Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
04/26/2012US20120100134 Genetic variants in angiogenesis pathway associated with clinical outcome
04/26/2012US20120100133 Use of anti-cd20 antibody for treating primary intraocular lymphoma
04/26/2012US20120100132 Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof
04/26/2012US20120100131 Method for treatment of blood tumor using anti-tim-3 antibody
04/26/2012US20120100128 Methods of and compositions for inhibiting the proliferation of mammalian cells
04/26/2012US20120100121 Pegylated L-Asparaginase
04/26/2012US20120100111 Method for treating cancer
04/26/2012US20120100109 Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
04/26/2012US20120100103 In situ forming hydrogel and biomedical use thereof
04/26/2012US20120100102 Cancer vaccine
04/26/2012US20120100101 Ctla-4 antibody dosage escalation regimens
04/26/2012US20120100077 Mixture of amphipathic molecules and method for modifying cell membranes by means of fusion
1 ... 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 ... 2211